Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Journal of Child and Adolescent Psychopharmacology|May 13, 2014
A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorderSarah D Atkinson, Apurva Prakash, Qi Zhang, et al.Current Medical Research and Opinion|February 10, 2007
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority studyAndrew A Nierenberg, John H Greist, Craig H Mallinckrodt, et al.Journal of Child and Adolescent Psychopharmacology|May 16, 2015
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorderGraham J Emslie, Thomas G Wells, Apurva Prakash, et al.Bioanalysis|June 9, 2023
Microsampling in pediatric studies: pharmacokinetic sampling for baricitinib (Olumiant™) in global pediatric studiesEnaksha R Wickremsinhe, Rodney L Decker, Lisa B Lee, et al.Human Psychopharmacology|January 14, 2012
Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocolTina Marie Myers Oakes, Adam L Myers, Lauren B Marangell, et al.Current Medical Research and Opinion|July 30, 2008
The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorderDavid V Sheehan, Adam L Meyers, Apurva Prakash, et al.The British Journal of Dermatology|November 23, 2021
A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measuresJake Macey, Helen Kitchen, Natalie V J Aldhouse, et al.Journal of Child and Adolescent Psychopharmacology|January 19, 2012
An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depressionApurva Prakash, Evelyn Lobo, Christopher J Kratochvil, et al.The Journal of Dermatological Treatment|November 10, 2024
Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 yearsAndreas Wollenberg, Masanori Ikeda, Chia-Yu Chu, et al.The British Journal of Dermatology|March 31, 2023
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)Antonio Torrelo, Barbara Rewerska, Maria Galimberti, et al.Pageof 4